TransCode investor reports 5.16% ownership stake

TransCode Therapeutics, Inc. (RNAZ) has a beneficial ownership report from investor Daniel Eduardo Katzman, who reports beneficially owning 155,611 shares of the company's common stock, par value $0.0001 per share.

Rhea-AI Filing Summary

TransCode Therapeutics, Inc. (RNAZ) has a beneficial ownership report from investor Daniel Eduardo Katzman, who reports beneficially owning 155,611 shares of the company's common stock, par value $0.0001 per share.

This position represents 5.16% of the outstanding common stock. Katzman reports sole voting power and sole dispositive power over all 155,611 shares, with no shared voting or dispositive power.

Key Figures

Beneficially owned shares: 155,611 shares Percent of class: 5.16% Par value per share: $0.0001 per share +2 more

5 metrics

Beneficially owned shares 155,611 shares Common stock beneficially owned by Daniel Eduardo Katzman

Percent of class 5.16% Percentage of TransCode Therapeutics common stock class owned by Katzman

Par value per share $0.0001 per share Par value of TransCode Therapeutics common stock

Sole voting power 155,611 shares Shares over which Katzman has sole power to vote

Sole dispositive power 155,611 shares Shares over which Katzman has sole dispositive power

Key Terms

beneficially owned, sole voting power, sole dispositive power, percent of class, +1 more

5 terms

beneficially owned financial

"Item 4. | Ownership (a) | Amount beneficially owned: 155,611"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole voting power regulatory

"Sole Voting Power 155,611.00 6 | Shared Voting Power 0.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

sole dispositive power regulatory

"Sole Dispositive Power 155,611.00 8 | Shared Dispositive Power 0.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

percent of class financial

"Percent of class: 5.16 %"

Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.

CUSIP Number financial

"(e) | CUSIP Number(s): 89357L501"

A CUSIP number is a nine-character code that uniquely identifies a specific U.S. or Canadian stock, bond, or other security, similar to a barcode or a social-security number for a financial instrument. It matters to investors because it removes confusion between similar securities, ensures trades and settlements are applied to the correct issue, and helps locate official documents and transaction records quickly.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake in TransCode Therapeutics (RNAZ) does Daniel Eduardo Katzman report on this Schedule 13G?

Daniel Eduardo Katzman reports beneficial ownership of 155,611 shares of TransCode Therapeutics common stock, representing 5.16% of the class, according to the Schedule 13G ownership disclosure.

Does Daniel Eduardo Katzman have sole or shared voting power over his RNAZ shares?

The filing states that Daniel Eduardo Katzman has sole voting power over 155,611 shares of TransCode Therapeutics and no shared voting power, indicating full individual authority to vote these shares.

What dispositive power does Daniel Eduardo Katzman report over TransCode Therapeutics (RNAZ) shares?

Katzman reports sole dispositive power over 155,611 shares of TransCode Therapeutics common stock and no shared dispositive power, meaning he alone can decide whether and how to dispose of these shares.

What percentage of TransCode Therapeutics (RNAZ) common stock is reported as beneficially owned?

The Schedule 13G indicates that 5.16% of TransCode Therapeutics' common stock is beneficially owned by Daniel Eduardo Katzman, based on 155,611 shares of common stock.

What class of securities in TransCode Therapeutics (RNAZ) is covered by this beneficial ownership report?

The report covers common stock, par value $0.0001 per share, of TransCode Therapeutics, Inc., identified by CUSIP number 89357L501, with 155,611 shares reported as beneficially owned.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/28/2026 - 07:49 PM Accepted by SEC EDGAR 07/28/2026 - 07:48 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

TransCode Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

89357L501

(CUSIP Number)

07/23/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 89357L501

1

Names of Reporting Persons

Daniel Eduardo Katzman

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

ARGENTINA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 155,611.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 155,611.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

155,611.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.16 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: TransCode Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 6 Liberty Square, #2382, Boston, Massachusetts, 02109
Item 2.
(a)	Name of person filing: Daniel Eduardo Katzman
(b)	Address or principal business office or, if none, residence: Islandia 2397, Escobar Buenos Aires, CP 1625, Argentina
(c)	Citizenship: Argentina
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP Number(s): 89357L501
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 155,611
(b)	Percent of class: 5.16 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 155,611
	(ii) Shared power to vote or to direct the vote: 0.00
	(iii) Sole power to dispose or to direct the disposition of: 155,611
	(iv) Shared power to dispose or to direct the disposition of: 0.00
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Daniel Eduardo Katzman

Signature:	/s/ Daniel Eduardo Katzman
Name/Title:	Self
Date:	07/28/2026